Biodegradable ocular implants and methods for treating ocular conditions
Biodegradable ocular implants are described. The ocular implants include a bioactive agent that can be released within the eye to treat an ocular condition or indication. The implants can be used for the administration of a bioactive agent over prolonged periods of time. In some aspects the implants are formed of a matrix of natural biodegradable polysaccharides.
1 . A biodegradable implant for delivery of a bioactive agent to the interior of the eye, wherein the implant comprises a matrix comprising a biodegradable polymer and a bioactive agent which is capable of releasing a therapeutically effective amount of bioactive agent in the interior of the eye after a period of 30 days from implantation.
2 . The biodegradable implant of claim 1 which is configured so that it can be placed at a location in the inner eye using a sutureless procedure.
3 . The biodegradable implant of claim 1 wherein the biodegradable polymer comprises a natural biodegradable polysaccharide.
4 . The biodegradable implant of claim 1 wherein the matrix is formed from biodegradable polymers crosslinked via pendent polymerized groups.
5 . The biodegradable implant of claim 3 wherein the biodegradable polymer comprises a linear polymer having repeating glucopyranose units that are joined by α-1,4 linkages.
6 . The biodegradable implant of claim 1 wherein the biodegradable polymer has an average molecular weight of 50,000 Da or less.
7 . The biodegradable implant of claim 6 wherein the biodegradable polymer has an average molecular weight in the range of 1000 Da to about 10,000 Da.
8 . The biodegradable implant of claim 1 wherein the bioactive agent is a hydrophilic compound.
9 . The biodegradable implant of claim 1 wherein the bioactive agent is a polypeptide.
10 . The biodegradable implant of claim 9 wherein the bioactive agent is an antibody or an antibody fragment.
11 . The biodegradable implant of claim 1 wherein the bioactive agent is selected from the group consisting of alemtuzumab, gemtuzumab, rituximab, ibritumomab, tositumomab, edrecolomab, cetuximab, and bevacizumab, ranibizumab, satumomab, pertuzumab, and daclizumab.
12 . The biodegradable implant of claim 1 wherein the bioactive agent is selected from the group consisting of antiproliferative agents, anti-inflammatory agents, anti-angiogenic agents, hormonal agents, antibiotics, and neurotrophic factors.
13 . The biodegradable implant of claim 1 wherein the biodegradable polymer is present in the implant in an amount of 87.5% wt or greater.
14 . The biodegradable implant of claim 13 wherein the biodegradable polymer is present in the implant in an amount of 90% wt or greater.
15 . The biodegradable implant of claim 1 wherein the bioactive agent is present in the implant in an amount of up to 12.5% wt.
16 . The biodegradable implant of claim 15 wherein the bioactive agent is present in the implant in the range of 5% wt to 11% wt.
17 . A method for administering a bioactive agent to the inner eye, the method comprising the steps of:
providing a biodegradable implant comprising a matrix comprising a biodegradable polymer and a bioactive agent, wherein the implant is configured so that it can be placed at a location in the inner eye using a sutureless surgical procedure,
implanting the implant in the inner eye, and
maintaining the implant in the inner eye, wherein the implant releases a therapeutically useful amount of bioactive agent in the inner eye after a period of 30 days from the step of implanting.
18 . The method of claim 17 , wherein the step of implanting comprises implanting the biodegradable implant in the inner eye in a sutureless process.
19 . The method of claim 17 , wherein the step of maintaining, the implant releases a therapeutically useful amount of bioactive agent in the inner eye after a period of 60 days from the step of implanting.
20 . The method of claim 19 , wherein the step of maintaining, the implant releases a therapeutically useful amount of bioactive agent in the inner eye after a period of 120 days from the step of implanting.
21 . The method of claim 17 performed to treat an ocular condition or indication selected from the group consisting of retinal detachment, vascular occlusion, retinitis pigmentosa, proliferative vitreoretinopathy, diabetic retinopathy, uveitis, choroiditis, retinitis, age-related macular degeneration, vascular diseases, tumor growth, and neoplasms.
22 . A method for administering a bioactive agent to the inner eye, the method comprising the steps of:
providing a biodegradable implant comprising a matrix of natural biodegradable polysaccharides and a bioactive agent, and
implanting the implant in the interior of the eye, wherein the implant releases a therapeutically useful amount of bioactive agent in the inner eye.
23 . A bioactive agent-releasing biodegradable ocular implant comprising a matrix of natural biodegradable polysaccharides and bioactive agent within the matrix.
24 . A kit for placing a biodegradable implant in the inner eye, the kit comprising:
a biodegradable implant comprises a matrix comprising a biodegradable polymer and a bioactive agent which is capable of releasing a therapeutically effective amount of bioactive agent in the inner eye after a period of 30 days from implantation, and
an insertion instrument to provide the implant to a target site within the inner eye.
25 . The kit of claim 24 , wherein the insertion instrument comprises a needle having a size of 25 gauge or smaller in which the implant can be placed.